1206594-08-2 Usage
Uses
Used in Organic Synthesis:
Morpholine, 4-[1-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropyl]is used as a building block in organic synthesis for the creation of biologically active molecules. Its cyclopropyl and boronic acid functionalities contribute to the formation of diverse chemical structures with potential applications in various fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Morpholine, 4-[1-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropyl]serves as a valuable reagent for the synthesis of pharmaceuticals. Its unique structural features and reactivity enable the development of novel drug candidates with improved therapeutic properties.
Used in the Suzuki-Miyaura Cross-Coupling Reaction:
Morpholine, 4-[1-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropyl]is a key component in the Suzuki-Miyaura cross-coupling reaction, a widely used method for the synthesis of pharmaceuticals, agrochemicals, and materials. This reaction allows for the efficient formation of carbon-carbon bonds, facilitating the synthesis of complex molecular structures.
Used in Material Science:
In material science, Morpholine, 4-[1-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropyl]has potential applications due to its unique structural features. Its cyclopropyl and boronic acid functionalities can be utilized in the development of new materials with specific properties, such as improved stability or reactivity.
Used in Drug Discovery:
Morpholine, 4-[1-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropyl]plays a significant role in drug discovery, where its reactivity and structural features are harnessed to design and synthesize novel drug candidates. Its potential applications in this field include the development of new therapeutic agents for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1206594-08-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,6,5,9 and 4 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1206594-08:
(9*1)+(8*2)+(7*0)+(6*6)+(5*5)+(4*9)+(3*4)+(2*0)+(1*8)=142
142 % 10 = 2
So 1206594-08-2 is a valid CAS Registry Number.
1206594-08-2Relevant academic research and scientific papers
4,5-diphenyl isoxazole derivative as well as preparation method and application thereof
-
Paragraph 0097; 0124; 0125; 0126, (2017/06/02)
The invention discloses a 4,5-diphenyl isoxazole derivative as well as a preparation method and application thereof. Specifically, the invention relates to a 4,5-diphenyl isoxazole derivative of a structure represented by the formula (I), a stereoisomer or pharmaceutically acceptable salt of the derivative, wherein the definition of each substituent in the formula (I) is the same as that in a specification. Compounds of novel structures have the activity of inhibiting heat shock proteins HSP90, can be used for treating cancers, neurodegenerative diseases, inflammatory diseases, autoimmune diseases and ischemic brain injuries, and has wide application prospect.
NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
-
Page/Page column 71, (2010/04/03)
Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the Formula (I). These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotox in states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.
